Healthcare / BiotechnologyASX
$9.00
-0.26 (-2.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $35.9M · quality 82.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$454M
P/E
14.1x
↓EV/EBITDA
4.0x
↓ROE
15.0%
↑Gross Margin
83.3%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.1%
FCF CAGR
+1.1%
FCF margin
42.9%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $95.0M · net income $36.2M · FCF $40.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $95.0M | $95.0M | $88.2M | $78.3M | $65.7M |
| Net Income | $36.2M | $36.2M | $35.6M | $30.6M | $20.9M |
| EBITDA | $57.2M | $57.2M | $56.3M | $49.6M | $37.4M |
| EPS | 0.72 | 0.72 | 0.70 | 0.59 | 0.40 |
| Gross Margin | 83.3% | 83.3% | 88.6% | 88.8% | 84.0% |
| Operating Margin | 48.1% | 48.1% | 54.4% | 56.3% | 53.8% |
| Net Margin | 38.1% | 38.1% | 40.4% | 39.1% | 31.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Current Ratio | 14.64 | 14.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $40.8M | $40.8M | $31.5M | $35.9M | $39.4M |
| Returns | |||||
| ROE | 15.0% | 15.0% | 17.6% | 18.6% | 16.6% |
| Valuation | |||||
| P/E | 14.06 | 14.06 | 24.90 | 29.63 | 42.51 |
| EV/EBITDA | 4.02 | 4.02 | 12.52 | 15.15 | 20.54 |
| P/B | 1.88 | 1.88 | 4.37 | 5.51 | 7.07 |
| Growth & Yield | |||||
| Revenue Growth | 7.8% | 7.8% | 12.6% | 19.2% | — |
| EPS Growth | 2.9% | 2.9% | 18.1% | 46.7% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
3.6%
EPS terminal req.
$0.80
Spread vs growth
-0.7%
5Y implied EPS CAGR
6.1%
EPS terminal req.
$0.97
Spread vs growth
-3.3%
10Y implied EPS CAGR
8.0%
EPS terminal req.
$1.56
Spread vs growth
-5.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.9%
Start / end P/E
14.9x → 12.5x
EPS bridge
0.70 → 0.72
Residual
-0.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.